The tweet was deleted by the author.
But we saved everything 🙂.
Allogene Therapeutics announced that CEO Zachary Roberts, MD, PhD, provided an update on the company’s investigational drug pipeline and corporate strategy at the UBS Global Biopharma Conference in London.
The presentation is available for replay through the Investors section of the company’s website. Allogene is actively developing therapies in the cell therapy sector, aiming to advance treatments for cancer and other conditions.
View post on X Loading...
Earlier this year, Allogene Therapeutics unveiled an interim futility analysis for its ALPHA3 program and detailed an expansion of its allogeneic CART portfolio at SITC2026. The company has remained focused on advancing experimental cell therapies. Its pipeline development remains a key area of interest for stakeholders.